Bridgebio Pharma says it will seek U.S. approval of BBP-418 for LGMD2i after Phase 3 trial data showed a range of benefits ...
We recently published 10 Big Names Crushing Wall Street. BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the top-performing ...
H.C. Wainwright raised the firm’s price target on BridgeBio (BBIO) to $80 from $70 and keeps a Buy rating on the shares. The firm now includes ...
Zacks Investment Research on MSN
BridgeBio Pharma (BBIO) Soars 17.1%: Is Further Upside Left in the Stock?
BridgeBio Pharma (BBIO) shares ended the last trading session 17.1% higher at $63.56. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback